Resummary list

最新 100 件のみ表示中(全 3748 件)。 古い resummary は各 Summary YAML の synthesis_history で確認できます。

2026-07-28 (1 papers)

• Jia et al. CellDeathDis 2018 — The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth. (Basic-Others)

2026-07-27 (6 papers)

• Shin et al. ACSNano 2026 — Neutrophil-Like Mitochondria Enable Blood-Brain Barrier Transmigration and Neuroprotection. (Basic-Neutrophil and myeloid cell)
• Yue et al. JNeuroinflammation 2025 — Inhibition of neutrophil extracellular traps alleviates blood-brain barrier disruption and cognitive dysfunction via … (Basic-Neutrophil and myeloid cell)
• Yang et al. PLoSONE 2023 — A novel co-culture model for investigation of the effects of LPS-induced macrophage-derived cytokines on brain endoth… (Basic-Neutrophil and myeloid cell)
• Marques et al. CurrBiol 2024 — Lipocalins. (Basic-Others)
• Han et al. Immunity 2026 — Mammary tumors-derived exosomes induce striatal NF-κB signaling, microglial reactivity, and anxiety/depression-like b… (Basic-Others)
• Goo et al. JControlRelease 2026 — Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain… (Clinical-Others)

2026-07-26 (2 papers)

• Xin et al. CellBiomater 2026 — IL-4/C1q activated astrocyte-derived extracellular vesicles promote stroke infarct recovery by recruiting peripheral … (Basic-Extracellular vesicles)
• Wang et al. NatBiomedEng 2026 — Super homotypic targeting by surface engineering of extracellular vesicles. (Basic-Extracellular vesicles)

2026-07-24 (13 papers)

• Skribek et al. BrJCancer 2026 — The brain-lung immunotherapy prognostic (BLIP) score: a novel robust tool for prognostication in non-small cell lung … (Basic-Brain metastasis)
• Yuan et al. CancerCell 2026 — Rethinking immune states in brain metastasis (Basic-Brain metastasis)
• Chen et al. FrontOncol 2026 — Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolv… (Basic-Brain metastasis) review
• Jiang et al. FrontOncol 2026 — Advances in Ommaya reservoir-based intrathecal therapy for leptomeningeal metastasis from non-small cell lung cancer:… (Basic-Brain metastasis) review
• Hendrix et al. CancerCell 2026 — Extracellular vesicles: Whisperers of tumor immune evasion (Basic-Extracellular vesicles)
• Thery et al. JExtracellVesicles 2018 — Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International… (Basic-Extracellular vesicles) review
• Du et al. JNanobiotechnology 2026 — Plant-derived nanovesicles: the intelligent nanoplatforms for therapeutics and drug delivery (Basic-Extracellular vesicles) review
• Guo et al. Biomaterials 2026 — Synergistic immunotherapy of NSCLC enabled by a biomimetic nanodelivery system for autophagy-mediated MDSC reprogramm… (Basic-Neutrophil and myeloid cell)
• Bannister et al. Immunity 2026 — Lung lipids license neutrophils to grease the gate. (Basic-Neutrophil and myeloid cell)
• Nogales-Pons et al. JExpMed 2026 — Myeloid diversity in tumors: Shaped by genes, location, and time (Basic-Neutrophil and myeloid cell) review
• Ireland et al. CancerCell 2020 — MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate (Basic-Oncogene and genetics)
• Conrad et al. Cell 2026 — Cell death in cancer (Basic-Others) review
• King et al. NatRevDrugDiscov 2026 — Induced proximity-based therapeutic modalities. (Clinical-Others) review

2026-07-23 (6 papers)

• Lu et al. JClinOncol 2026 — Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-… (Basic-Brain metastasis)
• Schmidt et al. AmJPhysiolCellPhysiol 2026 — Extracellular Vesicles in Exhaled Breath Condensate as Emerging Biomarkers in Lung Cancer (Basic-Extracellular vesicles) review
• Nicola et al. Nature 2026 — Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity (Basic-Immunotherapy)
• Network et al. Cell 2015 — Genomic Classification of Cutaneous Melanoma (Basic-Others)
• Yue et al. NEnglJMed 2026 — Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. (Clinical-NSCLC-ALK)
• Planchard et al. AnnOncol 2018 — Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Clinical-NSCLC-Driver negative) review

2026-07-22 (3 papers)

• Bain et al. FrontImmunol 2026 — Tumor draining lymph nodes in non-small cell lung cancer: underrecognized role in biomarker discovery and therapeutic… (Basic-Tumor microenvironment) review
• Lu et al. ClinLungCancer 2026 — Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advan… (Clinical-NSCLC-EGFR)
• Peters et al. JClinOncol 2026 — First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results Fro… (Clinical-Novel modalities)

2026-07-21 (11 papers)

• Silva et al. FrontImmunol 2026 — Extracellular vesicles as prognostic biomarkers results of a neoadjuvant chemoimmunotherapy clinical trial in stage (Basic-Extracellular vesicles)
• Li et al. JCachexiaSarcopeniaMuscle 2026 — Cigarette Smoke-Exposed Alveolar Epithelial Cell-Derived Exosomes Exacerbate Skeletal Muscle Dysfunction Through HDAC… (Basic-Extracellular vesicles)
• Muro et al. SciAdv 2026 — A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle-based mRNA vaccines. (Basic-Immunotherapy)
• Song et al. SciAdv 2026 — Fibroblast-specific ablation of MHC-I antigen presentation via the IGF2 axis cripples CD8+ T cell surveillance in lun… (Basic-Immunotherapy)
• Suissa et al. NatMed 2026 — Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. (Basic-Others)
• de Marinis et al. LungCancer 2026 — Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert pan… (Clinical-NSCLC-Driver negative) review
• Liu et al. SciAdv 2026 — Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177Lu-labeled HER2 Fab radioconjugate. (Clinical-NSCLC-HER2)
• Mi et al. ExpertOpinBiolTher 2026 — Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer. (Clinical-Novel modalities) review
• Petrelli et al. LungCancer 2026 — Interstitial lung disease in patients treated with antibody-drug conjugates: a review. (Clinical-Novel modalities) review
• Amick et al. NatRevMolCellBiol 2026 — Cellular and signalling mechanisms that regulate the blood-brain barrier. (Clinical-Others) review
• Cutter et al. SciAdv 2026 — Vitronectin metabolically programs profibrotic macrophages in 3D cultures and idiopathic pulmonary fibrosis. (Clinical-Respiratory diseases)

2026-07-19 (1 papers)

• Hald et al. JAMA 2026 — Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. (Clinical-Others)

2026-07-18 (18 papers)

• Gonzalez-Kozlova et al. NatCommun 2026 — SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer’s disease. (Basic-Extracellular vesicles)
• Qian et al. Immunity 2026 — Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis. (Basic-Neutrophil and myeloid cell)
• Wang et al. NatMethods 2006 — Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. (Basic-Neutrophil and myeloid cell)
• Putzbach et al. SciAdv 2026 — Single-cell transcriptomic unveils tumor-mediated reprogramming of neutrophils and their unique vulnerability that in… (Basic-Neutrophil and myeloid cell)
• Chen et al. CancerCell 2026 — PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma. (Basic-Others)
• Banerjee et al. CancerImmunolRes 2026 — Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy. (Basic-Others)
• Ma et al. CancerImmunolRes 2026 — Elevated CHAF1A suppresses type I interferon production and causes immunotherapy resistance in esophageal squamous ce… (Basic-Others)
• Hao et al. CancerRes 2026 — Targeting WRN Helicase in Microsatellite Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosom… (Basic-Others)
• Cipriani et al. ClinCancerRes 2026 — Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer. (Basic-Others)
• Fang et al. JAMASurg 2026 — Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis … (Basic-Others)
• Khallaf et al. Nature 2026 — A queen odour mediates reproductive suppression in a eusocial mammal. (Basic-Others)
• Simo et al. Nature 2026 — Modular in vivo antibody-ADC click to reverse drug resistance in tumours. (Basic-Others)
• Mattiuz et al. Science 2026 — Dendritic cells control tertiary lymphoid structure development and maintenance in cancer. (Basic-Others)
• Rimner et al. JClinOncol 2026 — Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non-Small Cell Lung Cancer Ineligible … (Clinical-NSCLC-Driver negative)
• Haldar et al. CancerDiscov 2026 — First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. (Clinical-NSCLC-Driver-Other)
• Felip et al. CancerResCommun 2026 — Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-… (Clinical-Novel modalities)
• Kumar et al. NEnglJMed 2026 — Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. (Clinical-Others)
• Guo et al. NatCancer 2026 — PAPOLA-mediated hyperactive polyadenylation promotes leukemogenesis and leukemia stem cell self-renewal through metab… (Clinical-Others)

2026-07-17 (2 papers)

• Alamoudi et al. CancerRes 2026 — From Tissue Specificity to Systemic Cues: Shaping MYC‑Driven Tumor Metabolism. (Basic-Others)
• Zhang et al. ResSq 2025 — NK Cell-Derived Extracellular Vesicles Function as Immunomodulators to Regulate Breast Cancer Progression by Activati… (Clinical-Others)

2026-07-16 (1 papers)

• Khalaj et al. CancerImmunolRes 2026 — A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners. (Clinical-Others)

2026-07-10 (1 papers)

• Tarrago et al. CancerRes 2026 — Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis. (Basic-Others)

2026-07-08 (1 papers)

• Clusmann et al. CancerDiscov 2026 — Machine Learning Predicts Hepatocellular Carcinoma Risk from Routine Clinical Data: A Large Population-Based Multicen… (Basic-Immunotherapy)

2026-07-07 (25 papers)

• Gal et al. ClinCancerRes 2026 — Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma (Basic-Liquid-biopsy)
• Balogun et al. CancerDiscov 2026 — Pancreatic Cancer: Translating Tumor Biology into Actionability. (Basic-Others) review
• Min et al. CancerDiscov 2026 — AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. (Basic-Others)
• Ehara et al. CancerImmunolRes 2026 — Enhancement of ferroptosis in escape variant tumor cells by IFN-γ derived from antigen-specific T cells controls tumo… (Basic-Others)
• DelaCruz et al. CancerRes 2026 — A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific… (Basic-Others)
• Gu et al. Immunity 2026 — Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox r… (Basic-Others)
• Hu et al. Immunity 2026 — Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immuno… (Basic-Others)
• Sethakorn et al. JThoracOncol 2026 — Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensiv… (Basic-Others)
• Garitaonaindia et al. NatRevClinOncol 2026 — Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer. (Basic-Others) review
• Yadav et al. Nature 2014 — Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing (Basic-Others)
• Vaquero et al. Nature 2026 — TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer. (Basic-Others)
• Eshhar et al. ProcNatlAcadSciUSA 1993 — Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-bind… (Basic-Others)
• Kuganesan et al. SciAdv 2026 — A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC. (Basic-Others)
• Sun et al. SciAdv 2026 — Rapid evolution of lncRNAs introduces novel regulatory inputs into ancestral cancer pathways. (Basic-Others)
• Nowell et al. Science 1976 — The clonal evolution of tumor cell populations (Basic-Others)
• Norgard et al. JImmunotherCancer 2026 — Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy. (Basic-Tumor microenvironment)
• Group et al. Lancet 2010 — Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-a… (Clinical-NSCLC-Driver negative) review
• Brunetti et al. LancetOncol 2026 — Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in (Clinical-NSCLC-Driver negative)
• Lu et al. CancerImmunolRes 2026 — Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiat… (Clinical-NSCLC-Driver-Other)
• Yan et al. CellRepMed 2026 — High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system… (Clinical-NSCLC-EGFR)
• Reinhorn et al. JTOClinResRep 2026 — Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for… (Clinical-NSCLC-HER2)
• Rafei et al. NatRevImmunol 2026 — A guide to CAR T cell therapies: development, current status and future prospects. (Clinical-Novel modalities) review
• Huo et al. CancerImmunolRes 2026 — VISTA+ neutrophils contribute to platinum resistance by suppressing CD8+T cells in high-grade serous ovarian cancer. (Clinical-Others)
• Wu et al. CancerLett 2026 — Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMA… (Clinical-Others)
• Rovers et al. LancetOncol 2026 — Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a … (Clinical-Others)

2026-07-03 (2 papers)

• Rampotas et al. SciTranslMed 2026 — CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organo… (Clinical-Novel modalities)
• Fan et al. LancetOncol 2026 — Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases (Clinical-Others) review

2026-06-23 (1 papers)

• Costa-Silva et al. NatCellBiol 2015 — Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver (Basic-Extracellular vesicles)

2026-06-22 (1 papers)

• Lipson et al. NatMed 2012 — Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies (Clinical-NSCLC-Driver-Other)

2026-06-18 (2 papers)

• Chaft et al. JAMA 2026 — Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial (Clinical-NSCLC-Driver negative)
• Sethakorn et al. Cancer 2026 — The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer (Clinical-SCLC) review

2026-06-17 (2 papers)

• FDA 2011 — Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics (Clinical-Methodology)
• Jolliet et al. Thorax 1997 — Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predict… (Clinical-Respiratory diseases)

2026-06-16 (1 papers)

• Radovich et al. CancerCell 2018 — The Integrated Genomic Landscape of Thymic Epithelial Tumors (Clinical-Thymic)